www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

3SBio Group has always been committed to solving the problem of
clinical drug use for patients, constantly conquering the challenges
of the disease, using high-quality drugs to improve the quality of
life of patients, and working hard for the benefit of human health.

1993 1995 1996 1998 2002 2005 2006 2007 2009 2010 2011 2013 2014 2015 2016 2017

Chronicle of events

Beginning in 1993, 3SBio dares to innovate and pursues excellence. After 20 years of rapid development, 3SBio Group has now become a leading Chinese biopharmaceutical company that integrates R&D, production and sales, and has achieved great success in the international market.

  • 1993

    Shenyang Sunshine Pharmaceuticals Co., Ltd. was established.

    In 1993, Shenyang Sunshine Pharmaceuticals CO., Ltd was founded by the 58-year-old Major General Lou Dan and his team. Lou Dan is a member of the National Medical Review Committee, a well-known bioengineering medical expert and the previous director of the Institute of Microbiology and Immunology of Shenhou Military Medical Research Institute and served as the chairman and president as well as chief engineer of the company.

  • 1995

    In 1995, Intefen® (recombinant human interferon α2a injection) was launched. In 2000, Mr Lou Dan, founder of the company, first proposed that “To make the Interferon as affordable as penicillin for ordinary people”, whipping up price reduction storm in the bio-pharmaceutical industries

    In April 1995, Intefen was approved to be manufactured by CFDA.
    In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.

  • 1996

    Inleusin® (recombinant human interleukin-2 for injection) was listed

    In June 1995, CFDA production approval documents were obtained for Inleusin.
    This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

  • 1998

    EPIAO® (recombinant human erythropoietin injection (CHO cell)) was listed, which was one of the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market

    In 1998, EPIAO was marketed with approval of the CFDA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug.

  • 2002

    In 2002, SEPO® (recombinant human erythropoietin injection (CHO cell)) and SPARIN® (injectable low-molecular-weight heparin calcium) were listed and included in the product team of the Group in 2014

    CFDA production approval documents were obtained for SEPO in 2001.It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce. SPARIN was approved by the CFDA and listed in 2002.

  • 2005

    Co-founder Dr. Lou Jing led the research and development of TPIAO® as a new class of Chinese medicine (recombinant human thrombopoietin injection), which was listed and the only commercial platelet-derived growth factor in the world

    In 2005, TPIAO was listed and has been approved by the CFDA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

    The first antibody fusion protein in China, Etanercept® (recombinant human tumor necrosis factor-α receptor Ⅱ: IgG Fc fusion protein for injection) was listed, and was included in the product team of the Group in 2016

    Etanercept was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by the CFDA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

  • 2006

    Through Sunshine (Liaoning), we obtained the exclusive right to the distribution of iron sucrose injection for five years.

    Iron sucrose injection is a iron supplement product, and is currently the third largest source of revenue for us in China, following EPIAO and TPIAO.

    Our company was registered as an exempted company in the Cayman Islands.

  • 2007

    It is listed on NASDAQ

  • 2009

    Qiming granule (National protected traditional Chinese medicines) was listed for treatment of type II diabetic retinopathy simplex and was included in the product team of the Group in 2015

    Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.
    It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by the China Food and Drug Administration in 2013. Qiming granule is the first CFDA-approved new Chinese medicine for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.

  • 2010

    We completed the construction of additional production facilities for EPIAO and TPIAO in Shenyang Economic and Technological Development Zone.

    These facilities have been certified by the China Food and Drug Administration and comply with the major international regulatory guidelines (including regulations of the cooperation plan between European Food and Drug Administration and International Drug Inspection).These facilities have increased the production capacity of EPIAO and TPIAO by approximately four times.

  • 2011

    Jiannipai® (recombinant humanized anti-CD25 monoclonal antibody injection) was listed, and included in the product team of the Group in 2016

    Jiannipai is suitable for prevention of acute rejection after renal transplantation, which can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.

    The China Food and Drug Administration approved that we voluntarily upgrade product quality manufacturing standards of EPIAO to full compliance with European Pharmacopoeia standards.

  • 2013

    The company was privatized by the buyer group led by management and CITIC PE, and was delisted from NASDAQ.

  • 2014

    we acquired the Sciprogen Bio-pharmaceutical Co.,Ltd. based in China.

    We also acquired Sirton, a contract drug manufacturer based in Italy.

    We separately entered into a strategic cooperation agreement with CPGJ, and acquired approximately 6.96% of stock rights from CPGJ.

  • 2015

    Qiming granule was incorporated into the company's product group.

    Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.

    It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by the China Food and Drug Administration in 2013.Qiming granule is the first CFDA-approved new TCM drug for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.

    The company was listed on Hong Kong Stock Exchange, acquired Zhejiang Wansheng Pharmaceutical Co., Ltd. and was included in the Hang Seng Composite Large and Medium Stock Index.

  • 2016

    3SBio reached business cooperation with AstraZeneca. GLP-1 receptor agonists Byetta® (exenatide injection) and BydureonTM (exenatide sustained-releasing drug) were included in the product team of the Group for improving the glycemic control in patients with type II diabetes.

    On October 11, 2016, we have entered into an exclusive license agreement with AstraZeneca to obtain the commercial rights of Byetta and Bydureon in China, which are valid for 20 years.

    3SBio opened the strategic layout of collectivization, becoming the only bio-pharmaceutical enterprise shortlisted for TOP 100 Enterprises of Chinese Pharmaceutical Industry, and ranking the top 20 of Chinese Pharmaceutical R&D. It held 97.8% CPGJ shares and was included in the MSCI China Index

  • 2017

    TPIAO, Etanercept and Qiming granule were included in 2017 Medical Insurance Catalogue; Signed the exclusive license agreement with Lilly for insulin product Humuli; Raised 300 million Euros by issuing convertible bonds.